Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment

Details for Australian Patent Application No. 2008320822 (hide)

Owner Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.

Inventors Konthur, Zoltan; Skriner, Karl; Lehrach, Hans

Agent Davies Collison Cave

Pub. Number AU-A-2008320822

PCT Pub. Number WO2009/056633

Priority 07119810.5 31.10.07 EP

Filing date 31 October 2008

Wipo publication date 7 May 2009

International Classifications

G01N 33/564 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for pre-existing immune complex or autoimmune disease

G01N 33/68 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving proteins, peptides or amino acids

Event Publications

20 May 2010 PCT application entered the National Phase

  PCT publication WO2009/056633 Priority application(s): WO2009/056633

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008320823-Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)

2008320821-Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor